[{"id":"336b2a89-c159-43c3-97a3-1a3d4e0383e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01154335","created_at":"2021-01-18T04:35:39.864Z","updated_at":"2025-02-25T15:32:14.079Z","phase":"Phase 1","brief_title":"Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01154335","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" KRAS • ALK","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • linsitinib (ASP7487)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2022-05-03"},{"id":"00f37282-88de-4fc3-b91a-1df12b6d5136","acronym":"","url":"https://clinicaltrials.gov/study/NCT00889382","created_at":"2021-01-18T03:24:17.372Z","updated_at":"2024-07-02T16:36:53.424Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)","source_id_and_acronym":"NCT00889382","lead_sponsor":"Astellas Pharma Inc","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • linsitinib (ASP7487)"],"overall_status":"Completed","enrollment":" Enrollment 152","initiation":"Initiation: 08/05/2009","start_date":" 08/05/2009","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/25/2014","study_completion_date":" 08/25/2014","last_update_posted":"2019-11-19"},{"id":"4df1a9e2-4955-42a1-a861-a13e5b341fa9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01221077","created_at":"2021-01-18T04:54:20.608Z","updated_at":"2024-07-02T16:37:03.502Z","phase":"Phase 2","brief_title":"Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene","source_id_and_acronym":"NCT01221077","lead_sponsor":"Astellas Pharma Inc","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • linsitinib (ASP7487)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 04/08/2011","start_date":" 04/08/2011","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 09/01/2014","study_completion_date":" 09/01/2014","last_update_posted":"2019-01-24"},{"id":"4fe00c35-b65b-4356-9132-931ccb374a01","acronym":"","url":"https://clinicaltrials.gov/study/NCT01186861","created_at":"2021-01-18T04:44:45.330Z","updated_at":"2024-07-02T16:37:07.249Z","phase":"Phase 2","brief_title":"Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy","source_id_and_acronym":"NCT01186861","lead_sponsor":"Astellas Pharma Inc","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • linsitinib (ASP7487)"],"overall_status":"Completed","enrollment":" Enrollment 205","initiation":"Initiation: 03/04/2011","start_date":" 03/04/2011","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 03/11/2015","study_completion_date":" 03/11/2015","last_update_posted":"2018-09-05"}]